Evidence map›Paper›PMID 32707871›Full record

ArticleMicroorganisms2020

Comprehensive Host Cell-Based Screening Assays for Identification of Anti-Virulence Drugs Targeting

Julia von Ambüren, Fynn Schreiber, Julia Fischer, Sandra Winter, Edeltraud van Gumpel, Alexander Simonis, Jan Rybniker

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Julia von AmbürenDepartment I of Internal Medicine, University of Cologne, 50937 Cologne, Germany.
Fynn SchreiberDepartment I of Internal Medicine, University of Cologne, 50937 Cologne, Germany.
Julia FischerDepartment I of Internal Medicine, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0001-6138-7454
Sandra WinterCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Edeltraud van GumpelCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
Alexander SimonisDepartment I of Internal Medicine, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0003-2945-9897
Jan RybnikerDepartment I of Internal Medicine, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0001-8351-2690
University of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of bacterial pathogens being resistant to antibiotic treatment is increasing worldwide, leading to a severe global health challenge. Simultaneously, the development and approval of new antibiotics stagnated in the past decades, leading to an urgent need for novel approaches to avoid the spread of untreatable bacterial infections in the future. We developed a highly comprehensive screening platform based on quantification of pathogen driven host-cell death to detect new anti-virulence drugs targeting

Indexed as

antibiotic drug screeningantibiotic resistancehost-directed therapiesmultidrug-resistant pathogensPseudomonas aeruginosaSalmonella Typhimuriumtype 3 secretion system

Identifiers

PMID32707871
PMCPMC7463580
OpenAlexW3044724669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.